Dive Brief:
- As part of its efforts to streamline operations in India, Sandoz is closing an API plant in Mumbai.
- Sandoz, the generics division of Novartis, has emphasized that it remains committed to India.
- Sandoz has two additional plants in India, which will remain open.
Dive Insight:
Sandoz has emphasized that it will remain committed to India, despite the fact that it is closing the Mumbai plant. It has another API facility in Mahad, in addition to a facility in Kalwe, where oral solid dosage products are produced. Both of these facilities are located in the Maharashtra state and are very productive, with over 3 billion tablets produced.
The plant that is closing employs 170 workers, all of whom will lose their jobs.